-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Orsondor Medical announced the establishment of its second wholly-owned subsidiary, Orsondor Biotechnology Development (Shanghai) Co.
, Ltd.
, and the Orsondor Biotechnology Innovation Center was officially listed in Shanghai Pudong Waigaoqiao Free Trade Zone
.
Ms.
As the world’s leading in-vitro diagnostic company, Orsondor Medical has been adhering to the concept of "every test is about life" in the course of more than 80 years of development, and is committed to providing high-quality continuous innovations for global clinical laboratories and blood transfusions.
Medical institutions provide long-term outstanding value
.
After independence from Johnson & Johnson, Orson was successfully listed on the Nasdaq in the United States at the beginning of this year.
Long-term commitment to help Chinese creation go global
The biotechnology innovation center unveiled this time is an important innovation platform outside the R&D center of Orsondor headquarters.
It will focus on technology development and services in the fields of biotechnology and medical devices.
It is also Orsondor's integration of global innovation resources and full localization An important initiative for innovation
.
Relying on the platform technology advantages of the innovation center and regional industry collection resources, Orsondor plans to promote dozens of new products (including equipment and reagents) that meet the needs of China's local medical market in the next five years; at the same time, it plans to introduce talents, Increase local and international cooperation and other measures to further enhance the operational level in China and accelerate the construction of a "research-production-sales integrated ecosystem" in the Chinese market
Professor Cai Kui, Chairman of the Applied Evaluation Branch of the Chinese Medical Equipment Association, mentioned: “In recent years, under the development concept of modern laboratory science, the importance of in vitro diagnostics has been increasing, but with the increasing degree of aging of the population The clinic also puts forward higher requirements for testing technology and medical devices
.
Contemporary in vitro diagnostic companies not only need to fully understand the clinical and patient needs, so that testing can become a solid backing for clinical decision-making; at the same time, they also need to have considerable scientific research spirit and innovative capabilities.
Ms.
Lin Yan, President of Orcendor Medical Greater China, said: "The Chinese market is a crucial part of Orcendor's global innovation layout
.
We will launch major scientific research projects in the newly established Orcendor Biotechnology Innovation Center.
Take advantage of the east wind to explore the innovation model of China's localized market
With the in-depth advancement of the Healthy China 2030 strategy, a series of reform policies are piloted in the Waigaoqiao Free Trade Zone to provide policy support and reform assistance for biomedical companies
.
For example, in 2017, the medical device registrant system was piloted for the first time in the Shanghai Free Trade Zone.
Orsendo Medical actively responds to the national policy and will gradually establish a global R&D and production supply chain including China and the Asia-Pacific region through the establishment of the biotechnology innovation center to better serve the Chinese diagnostic market
.
At the end of 2020, Aosendo Medical Equipment Trading (China) Co.
, Ltd.
formally became one of the first 41 Global Operators Program (GOP) strategic cooperative enterprises in the Shanghai Free Trade Zone, and signed a global operator with the Shanghai Free Trade Zone Free Trade Zone Administration Plan a memorandum of strategic cooperation
.
Since then, the two parties have communicated and exchanged on the company's strategic positioning, functional innovation, financial support, import and export trade development, etc.
Zhang Hao, Deputy General Manager of Shanghai Waigaoqiao Group Co.
, Ltd.
and Chairman of the New Development Company, said in a speech: "Waigaoqiao Group and its subsidiary New Development Company, as a member of the global operator plan service class, will continue to cooperate with the bonded zone.
The Administration and various functional departments in the districts support the development of Orsondor in the Waigaoqiao Free Trade Zone, accurately meet various needs, play a role as a bridge between government and enterprises, and help Orsondor to respond to localization and accelerate the development of global business , In the process of building high-quality products and service solutions and promoting China's R&D to the world, Aosendo will provide the greatest support for sustainability, high quality and precision
.
"
Adhering to the concept of "every test is life", in the future, Orsondor Medical will continue to work with global partners to continue to focus on emergency testing and blood transfusion safety to build higher-quality products and service solutions, and use sustainable products and services Solutions and lean concepts, as well as strong local R&D capabilities, create dual-characteristic brand advantages for emergency and blood transfusion, provide long-term outstanding value, promote Chinese R&D to the world, and benefit more patients and customers
